de Montalembert Mariane, Ribeil Jean-Antoine, Brousse Valentine, Guerci-Bresler Agnes, Stamatoullas Aspasia, Vannier Jean-Pierre, Dumesnil Cécile, Lahary Agnès, Touati Mohamed, Bouabdallah Krimo, Cavazzana Marina, Chauzit Emmanuelle, Baptiste Amandine, Lefebvre Thibaud, Puy Hervé, Elie Caroline, Karim Zoubida, Ernst Olivier, Rose Christian
Pediatrics Department, Necker Children's Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Laboratory of Excellence GR-Ex, Paris, France.
PLoS One. 2017 Mar 3;12(3):e0172147. doi: 10.1371/journal.pone.0172147. eCollection 2017.
The risk and clinical significance of cardiac iron overload due to chronic transfusion varies with the underlying disease. Cardiac iron overload shortens the life expectancy of patients with thalassemia, whereas its effect is unclear in those with myelodysplastic syndromes (MDS). In patients with sickle cell anemia (SCA), iron does not seem to deposit quickly in the heart. Our primary objective was to assess through a multicentric study the prevalence of cardiac iron overload, defined as a cardiovascular magnetic resonance T2*<20 ms, in patients with thalassemia, SCA, or MDS. Patient inclusion criteria were an accurate record of erythrocyte concentrates (ECs) received, a transfusion history >8 ECs in the past year, and age older than 6 years. We included from 9 centers 20 patients with thalassemia, 41 with SCA, and 25 with MDS in 2012-2014. Erythrocytapharesis did not consistently prevent iron overload in patients with SCA. Cardiac iron overload was found in 3 (15%) patients with thalassemia, none with SCA, and 4 (16%) with MDS. The liver iron content (LIC) ranged from 10.4 to 15.2 mg/g dry weight, with no significant differences across groups (P = 0.29). Abnormal T2* was not significantly associated with any of the measures of transfusion or chelation. Ferritin levels showed a strong association with LIC. Non-transferrin-bound iron was high in the thalassemia and MDS groups but low in the SCA group (P<0.001). Hepcidin was low in thalassemia, normal in SCA, and markedly elevated in MDS (P<0.001). Two mechanisms may explain that iron deposition largely spares the heart in SCA: the high level of erythropoiesis recycles the iron and the chronic inflammation retains iron within the macrophages. Thalassemia, in contrast, is characterized by inefficient erythropoiesis, unable to handle free iron. Iron accumulation varies widely in MDS syndromes due to the competing influences of abnormal erythropoiesis, excess iron supply, and inflammation.
慢性输血所致心脏铁过载的风险及临床意义因基础疾病而异。心脏铁过载会缩短地中海贫血患者的预期寿命,而其对骨髓增生异常综合征(MDS)患者的影响尚不清楚。在镰状细胞贫血(SCA)患者中,铁似乎不会迅速沉积在心脏中。我们的主要目标是通过一项多中心研究评估心脏铁过载(定义为心血管磁共振T2*<20 ms)在地中海贫血、SCA或MDS患者中的患病率。患者纳入标准为准确记录接受的红细胞浓缩物(EC)、过去一年输血史>8个EC以及年龄大于6岁。2012 - 2014年,我们从9个中心纳入了20例地中海贫血患者、41例SCA患者和25例MDS患者。红细胞单采术并不能始终预防SCA患者的铁过载。在地中海贫血患者中发现3例(15%)存在心脏铁过载,SCA患者中未发现,MDS患者中有4例(16%)。肝脏铁含量(LIC)范围为10.4至15.2 mg/g干重,各组间无显著差异(P = 0.29)。异常T2*与任何输血或螯合指标均无显著关联。铁蛋白水平与LIC密切相关。非转铁蛋白结合铁在地中海贫血和MDS组中较高,而在SCA组中较低(P<0.001)。地中海贫血患者的铁调素水平较低,SCA患者正常,MDS患者显著升高(P<0.001)。有两种机制可以解释为何SCA患者心脏中铁沉积较少:高水平的红细胞生成可使铁循环利用,慢性炎症使铁保留在巨噬细胞内。相比之下,地中海贫血的特点是红细胞生成效率低下,无法处理游离铁。由于异常红细胞生成、铁供应过多和炎症的相互竞争影响,MDS综合征中铁的积累差异很大。